Oncolin Therapeutics Signs Agreement with Leading Cancer Center
News Jun 12, 2008
Oncolin Therapeutics, Inc. has announced that it has signed a sponsored research agreement with The University of Texas M. D. Anderson Cancer Center (UTMDACC) in Houston, Texas to support work in the laboratory of Prof. Waldemar Priebe.
This new sponsored research will focus on the development of a new novel class of compounds that inhibit glycolysis, the metabolic pathway essential to the survival of many human tumors.
The company will have a right to an exclusive license to any new patents derived from this research as the company expands its support of Dr. Priebe’s drug discovery and development efforts.
This sponsored research will initially focus on evaluation of the selected lead compounds with the goal of identifying a superior inhibitor of glycolysis that potently blocks tumor growth.
Professor Waldemar Priebe is a world renowned scientist who has several drugs in clinical development based on research from his laboratory and works at UTMDACC, which is the world’s premier cancer center.
“Oncolin is committed to the research in Dr. Priebe’s laboratory in this important area of glycolysis inhibition for cancer treatment. This agreement expands our commitment to this area of cancer research and our goal of bringing the best drug in this therapeutic class into clinical development for patients,” said Dr Donald Picker, Chief Operating Officer of Oncolin.
About 422 million people around the world, including more than 30 million Americans, have diabetes. Obesity is the most significant risk factor for type 2 diabetes. yet about 30 percent of obese people do not develop type 2 diabetes or other metabolic conditions. New research aims to understand on a cellular level, how this separation occurs.READ MORE
Measuring hand grip can help identify youths who could benefit from lifestyle changes, says new research. While other studies have shown that muscle weakness as measured by grip strength is a predictor of unhealthy outcomes - including cardiovascular and metabolic diseases - this is the first to do so for adolescent health over time.READ MORE
Virtually all functions in our bodies require precise interactions between radically different types of molecules. A new study aims to understand how RNA molecules pair with intended protein partners. Researchers hope that they eventually will be able to predict and manipulate these partnerships that have been carved through millions of years of evolution.READ MORE